Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
Date:8/9/2011

SAN DIEGO, Aug. 9, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the second quarter ended June 30, 2011.

"We view the results from the Pathology Working Group's re-adjudication and the CSF study as important steps toward our planned response to the lorcaserin complete response letter," stated Jack Lief, Arena's President and Chief Executive Officer. "We are working to complete the remaining activities in order to submit our response around year end."

Research and development expenses continued to decline in the second quarter of 2011 to $14.7 million, compared to $20.5 million in the second quarter of 2010. Research and development expenses in the first half of 2011 declined to $30.6 million from $38.8 million in the first half of 2010. This decrease is primarily attributable to Arena's 2011 workforce reduction and ongoing cost-containment efforts, as well as completion of the Phase 3 lorcaserin clinical trials. General and administrative expenses totaled $6.1 million in the second quarter of 2011, compared to $6.8 million in the second quarter of 2010, and $13.0 million in the first half of 2011, compared to $13.8 million in the first half of 2010. Arena recorded restructuring charges of $3.5 million in the first half of 2011 related to its 2011 workforce reduction.

Total interest and other expense in the first half of 2011 increased to $17.6 million, compared to $7.8 million in the first half of 2010. This increase is primarily attributable to a non-cash loss on extinguishment of debt of $10.5 million resulting from Arena's principal prepayments on its Deerfield loan of $20.0 million in January 2011 and $17.7 million in March 2011. Total interest expense of $7.9 million was recorded in the first half of 2011, compared to $9.9 million in the first half of 2010. This decrease is primarily attributable to the
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
2. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
3. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
4. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
5. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
6. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
7. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
9. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
10. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... N.J. , July 30, 2014  InnoPharma, Inc. ... Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in ... agitation and disturbed behaviors in patients with schizophrenia or ... this generic injectable drug, InnoPharma has entered into an ... Sandoz Canada will make, use, sell, market and ...
(Date:7/30/2014)... Mass. , July 30, 2014 Cynosure, ... laser- and light-based aesthetic treatments for non-invasive and minimally invasive ... Executive Vice President, Chief Operating Officer and Chief Financial Officer ... effective August 1, 2014.  Baker, 53, will continue to serve ... Michael Davin , who remains Chairman and Chief Executive ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... N.Y., Feb. 6, 2012 /PRNewswire-iReach/ -- SalesCongo ... announced today it has named Kenneth R. Kaisen as its ... as a technology industry veteran with over 25 years of ... Vertis Communications, a marketing communications company. He was previously CEO ...
... (NYSE: CBM, "Cambrex") is pleased to announce that Greg Sargen, ... presentation on the Company at the UBS 22nd Annual Global ... EST at the Grand Hyatt New York, New York City. ... Cambrex website http://www.cambrex.com in the Investors section of ...
Cached Medicine Technology:SalesCongo Names Ken Kaisen CEO 2
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early part of ... people, in 2008 he suffered extreme financial hardship and lost ... carefully studied the difference between people who have sustainable and ... the knowledge he acquired, he was able to use what ... but also grow his clients' personal and financial assets while ...
(Date:7/30/2014)... WHAT: , Resistance to artemisinin, the main drug ... Asia, among the Plasmodium falciparum ( ... and is likely caused by a genetic mutation ... artemisinin-based combination therapyas opposed to a standard three-day ... cases, according to findings published today in the ...
(Date:7/30/2014)... 2014 Volunteers from the Church of ... abuse this summer with massive distribution of Truth ... find these volunteers on Strøget, the famous Copenhagen walking ... its shopping and its ambiance, some quarter of a ... summer day. , These activities are part of ...
(Date:7/30/2014)... Pennsylvania (PRWEB) July 30, 2014 Visitors ... have contributed over $8,500 to ensure its protection. Bob ... presents a check to the Delaware Highlands Conservancy for ... program. The small $2-per-stay donations add up fast, as ... of the Upper Delaware River Region. , The Kiesendahl ...
(Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
Breaking Medicine News(10 mins):Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2
... , ... ... ... ...
... to physical function but also extend to neurological function, according ... Journals of Gerontology Series A: Biological and Medical Sciences ... collection of ten articles highlighting new findings related to obesity ... of improved medical management of cardiovascular disease is that many ...
... procedures annually may improve life expectancy, study finds ... with both mammography and MRI appears to be a ... high risk for breast cancer, U.S. researchers say. , ... at Massachusetts General Hospital in Boston, and colleagues used ...
... physician shortages, researchers say, , TUESDAY, Feb. 23 (HealthDay News) -- ... a sharp decline in the average number of hours they work ... 1996, the average work week of doctors remained steady, but between ... work dropped nearly four hours a week -- from 54.9 to ...
... ... ... , ... , , , ...
... ... ... ... , ...
Cached Medicine News:Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 2Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 3Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 4Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 5Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 6Health News:UMDNJ's Health Information Management Program Trains Students for Careers in Fast-Growing Field 7Health News:Overweight middle-aged adults at greater risk for cognitive decline in later life 2Health News:Mammogram Plus MRI Cost-Effective in High-Risk Women 2Health News:Doctors Working Less, Earning Less 2Health News:Doctors Working Less, Earning Less 3Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 2Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 3Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 4Health News:Psychologists Say New Jersey's Largest Health Plan Violates Patient Privacy, Restricts Access to Care and Wastes Taxpayer Money 5Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 2Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: